Samjin Pharmaceutical created a specialty care (SC) unit and hired outside talent to strengthen its high value-added prescription drug business, including cancer drugs and rare disease treatments.
Samjin Pharmaceutical said on the 23rd that it hired Seo Young-hyun, a director at Antengene Korea, as head of the newly established SC unit.
Seo will oversee strategy to expand the SC portfolio, including cancer drugs, pulmonary arterial hypertension treatments and rare disease therapies.
Seo, who graduated from Yonsei University with degrees in economics and applied statistics, handled commercial strategy for hematologic and solid tumor portfolios, collaboration with key opinion leaders at tertiary general hospitals, and reimbursement expansion at Novartis Korea and Samsung Bioepis.
Seo later led marketing and sales organizations for the rare disease business at Shire Korea and Takeda Pharmaceutical Korea, and served as commercial lead at Antengene Korea.
Samjin Pharmaceutical plans to use this appointment to expand its product portfolio around high value-added therapeutic areas and strengthen its foundation for entering new markets.
President Kim Sang-jin of Samjin Pharmaceutical said, "The SC unit is a core business organization that will drive mid- to long-term revenue," adding, "We expect that bringing in professionals with deep understanding of cancer, pulmonary arterial hypertension and rare diseases will help new pipelines gain a foothold in the market and lay a foundation for continued growth."